S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in

Virios Therapeutics Stock Forecast, Price & News

-0.01 (-0.13 %)
(As of 01/21/2021 12:00 AM ET)
Today's Range
Now: $7.74
50-Day Range N/A
52-Week Range
Now: $7.74
Volume125,478 shs
Average Volume323,975 shs
Market Capitalization$60.62 million
P/E RatioN/A
Dividend YieldN/A
Virios Therapeutics, LLC, a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Its lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, LLC in July 2020. Virios Therapeutics, LLC was founded in 2012 and is headquartered in Alpharetta, Georgia.


Overall MarketRank

1.33 out of 5 stars

Medical Sector

645th out of 1,926 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:VIRI



Sales & Book Value

Annual SalesN/A



Market Cap$60.62 million
Next Earnings DateN/A
OptionableNot Optionable
-0.01 (-0.13 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VIRI News and Ratings via Email

Sign-up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Virios Therapeutics (NASDAQ:VIRI) Frequently Asked Questions

What stocks does MarketBeat like better than Virios Therapeutics?

Wall Street analysts have given Virios Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Virios Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Virios Therapeutics' CEO?

1,448 employees have rated Virios Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Virios Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Virios Therapeutics' key competitors?

Who are Virios Therapeutics' key executives?

Virios Therapeutics' management team includes the following people:
  • Mr. Greg Duncan, Chairman & CEO (Age 55)
  • Dr. William L. Pridgen, Chief Exec. Officer (Age 59)
  • Mr. Richard Burch, Pres (Age 64)
  • Ms. Angela Walsh, VP of Fin. & Treasurer (Age 54)
  • Mr. Ralph D. Grosswald, VP of Operations (Age 51)
  • Ms. Carol Duffy Ph.D., Chief Scientific Advisor
  • Dr. R. Michael Gendreau, Chief Medical Officer (Age 65)

When did Virios Therapeutics IPO?

(VIRI) raised $30 million in an initial public offering on Thursday, December 17th 2020. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO.

What is Virios Therapeutics' stock symbol?

Virios Therapeutics trades on the NASDAQ under the ticker symbol "VIRI."

When does Virios Therapeutics' quiet period expire?

Virios Therapeutics' quiet period expires on Tuesday, January 26th. Virios Therapeutics had issued 3,000,000 shares in its initial public offering on December 17th. The total size of the offering was $30,000,000 based on an initial share price of $10.00. During Virios Therapeutics' quiet period, insiders and underwriters that worked on the IPO are prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Virios Therapeutics?

Shares of VIRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Virios Therapeutics' stock price today?

One share of VIRI stock can currently be purchased for approximately $7.74.

How big of a company is Virios Therapeutics?

Virios Therapeutics has a market capitalization of $60.62 million. Virios Therapeutics employs 4 workers across the globe.

What is Virios Therapeutics' official website?

The official website for Virios Therapeutics is www.virios.com.

How can I contact Virios Therapeutics?

The company can be reached via phone at 866-620-8655.

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.